2010
Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial
Rosenheck R, Davis S, Covell N, Essock S, Swart M, Stroup S, McEvoy J, Lieberman J. Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2010, 8: 561-569. DOI: 10.1176/foc.8.4.foc561.Peer-Reviewed Original ResearchGreater weight gainNew medicationsOutcome measuresWeight gainNeurological side effectsAdditional outcome measuresPotential confounding factorsQuality of lifeStudy drugPrevious medicationCATIE trialMultivariate adjustmentImprove OutcomesMedicationsSide effectsOlanzapinePatientsConfounding factorsDrugsHealth costsOutcomesSignificant differencesRisperidoneCATIEMixed modelsFamily outcomes
Perlick D, Kaczynski R, Rosenheck R. Family outcomes. 2010, 133-155. DOI: 10.1017/cbo9780511712265.009.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsFamily outcomesDrugsPharmaceutical companiesSpecific outcomesOutcomesStatistical analysisCliniciansExtrapyramidal side effects
Caroff S, Miller D, Rosenheck R. Extrapyramidal side effects. 2010, 156-172. DOI: 10.1017/cbo9780511712265.010.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersExtrapyramidal side effectsDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsSide effectsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisCliniciansConclusion and implications for practice and policy
Rosenheck R, Stroup T, Lieberman J. Conclusion and implications for practice and policy. 2010, 288-306. DOI: 10.1017/cbo9780511712265.018.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisClinicians
2007
Generic Fluoxetine and Choice of Antidepressant Medication
Sernyak M, Rosenheck R. Generic Fluoxetine and Choice of Antidepressant Medication. Psychiatric Services 2007, 58: 128-130. PMID: 17215423, DOI: 10.1176/ps.2007.58.1.128.Peer-Reviewed Original Research
2006
Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos M, Glick I, Miller A, Hamner M, Miller D, Patel J, Tapp A, Keefe R, Rosenheck R. Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. Psychiatric Services 2006, 57: 1094-1101. PMID: 16870959, DOI: 10.1176/ps.2006.57.8.1094.Peer-Reviewed Original ResearchConceptsConcomitant psychotropic medicationsPsychotropic medicationsConcomitant medication useIntervention Effectiveness (CATIE) trialOnly partial responseSecond-generation antipsychoticsBetter neurocognitive functioningClinical Antipsychotic TrialsPartial responseCATIE trialMedication useAnticholinergic drugsBaseline useMedication dataMood stabilizersCases symptomsConcomitant useEffectiveness trialAntipsychotic TrialsMedicationsNeurocognitive functioningSchizophreniaBaseline dataTrialsAntipsychotics
2001
Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System
Leslie D, Rosenheck R. Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System. Medical Care 2001, 39: 923-933. PMID: 11502950, DOI: 10.1097/00005650-200109000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAntipsychotic AgentsComorbidityDelivery of Health Care, IntegratedDiagnosis, Dual (Psychiatry)FemaleGuideline AdherenceHumansMaleMental Health ServicesMiddle AgedNational Health ProgramsOutcome and Process Assessment, Health CarePatient CompliancePolypharmacyPractice Guidelines as TopicSchizophreniaUnited StatesUnited States Department of Veterans AffairsConceptsPatient Outcomes Research TeamLarger mental health systemMultiple antipsychotic medicationsAntipsychotic medicationPORT recommendationsSchizophrenia Patient Outcomes Research TeamVeterans AffairsHealth systemTotal weekly doseTreatment of schizophreniaPrescription drug recordsMental health systemHealth care systemGeneralized estimation equationsMultiple antipsychoticsNational Health SystemOlder patientsWeekly doseNational health care systemPharmacy dataComorbid depressionTreatment recommendationsDrug recordsMedicationsPatientsPerceived Needs and Service Use of Spanish Speaking Monolingual Patients Followed at a Hispanic Clinic
Diaz E, Prigerson H, Desai R, Rosenheck R. Perceived Needs and Service Use of Spanish Speaking Monolingual Patients Followed at a Hispanic Clinic. Community Mental Health Journal 2001, 37: 335-346. PMID: 11482751, DOI: 10.1023/a:1017552608517.Peer-Reviewed Original ResearchMeSH KeywordsAdultCommunication BarriersCommunity Mental Health CentersConnecticutCross-Sectional StudiesCultural DiversityEducational StatusFemaleHealth Care SurveysHealth Services, IndigenousHispanic or LatinoHumansLanguageMaleMiddle AgedNeeds AssessmentPatient CompliancePsychotropic DrugsSurveys and QuestionnairesConceptsMonolingual patientsPhysical health care providersMental health centersHealth care providersClinic patientsHealth centersAdditional interventionsCare providersService useHealth needsSociodemographic characteristicsNon-HispanicsPatientsClinicPerceived NeedsHispanicsPersistent effectsLow levelsBetter accessGreat needMedicationsMore difficultyLanguage barriersThe Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia
LESLIE D, ROSENHECK R. The Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. The Journal Of Nervous And Mental Disease 2001, 189: 377-383. PMID: 11434638, DOI: 10.1097/00005053-200106000-00005.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAntipsychotic AgentsBenzodiazepinesBudgetsClozapineComorbidityDepressive DisorderDrug CostsFemaleHealth Care CostsHealth FacilitiesHumansMaleMiddle AgedOlanzapinePirenzepinePractice Patterns, Physicians'Regression AnalysisRisperidoneSchizophreniaTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAtypical antipsychotic medicationsTreatment of schizophreniaAtypical antipsychoticsAntipsychotic medicationExpensive atypical antipsychotic medicationsVeterans AffairsPrescription drug recordsGeneralized estimation equationsDrug recordsPatientsReduced likelihoodAntipsychoticsMedicationsFacility characteristicsSchizophreniaAtypicalsFinal sampleTreatmentOlanzapineRisperidone
1998
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer J, Rosenheck R. Compliance With Medication Regimens for Mental and Physical Disorders. Psychiatric Services 1998, 49: 196-201. PMID: 9575004, DOI: 10.1176/ps.49.2.196.Peer-Reviewed Original ResearchConceptsMedication complianceCompliance rateMicroelectronic monitoringMedication regimensPhysical disordersPsychiatric treatmentMedication compliance ratesDiscontinuation of medicationMean compliance rateAntidepressant medicationPill countAntipsychotic medicationNonpsychiatric disordersPatient compliancePsychiatric disordersPatientsPsychiatric patientsClinician judgmentMedicationsDisordersRegimensLower ratesTreatmentReportPercent